GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Equity-to-Asset

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Equity-to-Asset : 0.28 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Maravai LifeSciences Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $416.8 Mil. Maravai LifeSciences Holdings's Total Assets for the quarter that ended in Dec. 2023 was $1,487.5 Mil. Therefore, Maravai LifeSciences Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.28.

The historical rank and industry rank for Maravai LifeSciences Holdings's Equity-to-Asset or its related term are showing as below:

MRVI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07   Med: 0.24   Max: 0.28
Current: 0.28

During the past 6 years, the highest Equity to Asset Ratio of Maravai LifeSciences Holdings was 0.28. The lowest was 0.07. And the median was 0.24.

MRVI's Equity-to-Asset is ranked worse than
76.29% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs MRVI: 0.28

Maravai LifeSciences Holdings Equity-to-Asset Historical Data

The historical data trend for Maravai LifeSciences Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Equity-to-Asset Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.25 0.07 0.16 0.24 0.28

Maravai LifeSciences Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.23 0.23 0.23 0.28

Competitive Comparison of Maravai LifeSciences Holdings's Equity-to-Asset

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maravai LifeSciences Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Equity-to-Asset falls into.



Maravai LifeSciences Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Maravai LifeSciences Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=416.753/1487.45
=0.28

Maravai LifeSciences Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=416.753/1487.45
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maravai LifeSciences Holdings  (NAS:MRVI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Maravai LifeSciences Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Executives
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii officer: See remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy officer: See Remarks 1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull director, officer: Chief Executive Officer 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack officer: General Counsel 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121